-transparent.png){kind=logo}
Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells of the loop of Henlé. The enzyme has a low affinity for glucose, and under normal conditions it processes little substrate. However, in diabetes mellitus, the marked rise in intracellular glucose that occurs in some cells causes marked production of sorbitol. The increased flux and accumulation of sorbitol is damaging to cells and may result in some of the long-term complications of diabetes. In this review, David Tomlinson, Elizabeth Stevens and Lara Diemel discuss the role of aldose reductase and the potential of its inhibitors as therapeutic agents targeted at chronic diabetic complications.
D R Tomlinson, and
E J Stevens, and
L T Diemel
August 1987,
The American journal of medicine,
D R Tomlinson, and
E J Stevens, and
L T Diemel
January 1992,
Pharmacology & therapeutics,
D R Tomlinson, and
E J Stevens, and
L T Diemel
June 1990,
Clinical pharmacy,
D R Tomlinson, and
E J Stevens, and
L T Diemel
December 1999,
Expert opinion on investigational drugs,
D R Tomlinson, and
E J Stevens, and
L T Diemel
October 2007,
The Cochrane database of systematic reviews,
D R Tomlinson, and
E J Stevens, and
L T Diemel
January 2023,
Current diabetes reviews,
D R Tomlinson, and
E J Stevens, and
L T Diemel
July 2021,
Archives of pharmacal research,
D R Tomlinson, and
E J Stevens, and
L T Diemel
October 2006,
Current opinion in investigational drugs (London, England : 2000),
D R Tomlinson, and
E J Stevens, and
L T Diemel
January 2008,
Asia Pacific journal of clinical nutrition,
D R Tomlinson, and
E J Stevens, and
L T Diemel
January 2016,
Mini reviews in medicinal chemistry,
